Experimental Cerenkov luminescence tomography of the mouse model with SPECT imaging validation

Hu, Zhenhua; Liang, Jimin; Yang, Weidong; Fan, Weiwei; Li, Congye; Chen, Xueli; Ma, Xiaolong; Li, Xiangsi; Qu, Xiaobo; Wang, Jing; Cao, Feng; Hui, Hui

doi:10.1364/oe.18.024441

Cited by 118 publications

(86 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CLI is emerging as a promising molecular imaging technique that has found potentials in many basic science research applications and even clinical use 4,5,15,16,17 . The major advantages of CLI over traditional nuclear imaging modalities such as PET stem from its use of OI instruments, which are easier to use, characterized by short acquisition time and high throughput, significantly less expensive, and more widely available to researchers.…”

Section: Discussionmentioning

confidence: 99%

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Liu

Chang

et al. 2012

JoVE

View full text Add to dashboard Cite

In molecular imaging, positron emission tomography (PET) and optical imaging (OI) are two of the most important and thus most widely used modalities [1][2][3] . PET is characterized by its excellent sensitivity and quantification ability while OI is notable for non-radiation, relative low cost, short scanning time, high throughput, and wide availability to basic researchers. However, both modalities have their shortcomings as well. PET suffers from poor spatial resolution and high cost, while OI is mostly limited to preclinical applications because of its limited tissue penetration along with prominent scattering optical signals through the thickness of living tissues.Recently a bridge between PET and OI has emerged with the discovery of Cerenkov Luminescence Imaging (CLI) [4][5][6] . CLI is a new imaging modality that harnesses Cerenkov Radiation (CR) to image radionuclides with OI instruments. Russian Nobel laureate Alekseyevich Cerenkov and his colleagues originally discovered CR in 1934. It is a form of electromagnetic radiation emitted when a charged particle travels at a superluminal speed in a dielectric medium 7,8 . The charged particle, whether positron or electron, perturbs the electromagnetic field of the medium by displacing the electrons in its atoms. After passing of the disruption photons are emitted as the displaced electrons return to the ground state. For instance, one Since its emergence, CLI has been investigated for its use in a variety of preclinical applications including in vivo tumor imaging, reporter gene imaging, radiotracer development, multimodality imaging, among others 4,5,9,10,11 . The most important reason why CLI has enjoyed much success so far is that this new technology takes advantage of the low cost and wide availability of OI to image radionuclides, which used to be imaged only by more expensive and less available nuclear imaging modalities such as PET.Here, we present the method of using CLI to monitor cancer drug therapy. Our group has recently investigated this new application and validated its feasibility by a proof-of-concept study 12 . We demonstrated that CLI and PET exhibited excellent correlations across different tumor xenografts and imaging probes. This is consistent with the overarching principle of CR that CLI essentially visualizes the same radionuclides as PET. We selected Bevacizumab (Avastin; Genentech/Roche) as our therapeutic agent because it is a well-known angiogenesis inhibitor 13,14 . Maturation of this technology in the near future can be envisioned to have a significant impact on preclinical drug development, screening, as well as therapy monitoring of patients receiving treatments. Video LinkThe video component of this article can be found at http://www.jove.com/video/4341/ Protocol 1. Tumor Model 1. Culture H460 cells (American Type Culture Collection) in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin (Invitrogen Life Technologies). It should be noted that the choices of cell lines, culture medium...

show abstract

Section: Discussionmentioning

confidence: 99%

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Liu

Chang

et al. 2012

JoVE

View full text Add to dashboard Cite

show abstract

“…Using the same radionuclide, Hu et al performed a more thorough validation project of radioactive OI using SPECT along with an optical-CT multimodality system (16). They quantified CLI and SPECT signals by imaging radioactive sources consisting of glass vessels filled with a gradient amount of Na 131 I, and the analysis showed an excellent correlation between the 2 modalities (radiance vs. counts/s, R 2 5 0.98).…”

Section: Spect/ctmentioning

confidence: 99%

Harnessing the Power of Radionuclides for Optical Imaging: Cerenkov Luminescence Imaging

Xu¹,

Liu²,

Cheng³

2011

J Nucl Med

129

178

View full text Add to dashboard Cite

Over the past several years, nuclear imaging modalities such as PET and SPECT have received much attention because they have been instrumental not only in preclinical cancer research but also in nuclear medicine. Yet nuclear imaging is limited by high instrumentation cost and subsequently low availability to basic researchers. Cerenkov radiation, a relativistic physical phenomenon that was discovered 70 years ago, has recently become an intriguing subject of study in molecular imaging because of its potential in augmenting nuclear imaging, particularly in preclinical small-animal studies. The intrinsic capability of radionuclides emitting luminescent light from decay is promising because of the possibility of bridging nuclear imaging with optical imaging-a modality that is much less expensive, is easier to use, and has higher throughput than its nuclear counterpart. Thus, with the maturation of this novel imaging technology using Cerenkov radiation, which is termed Cerenkov luminescence imaging, it is foreseeable that advances in both nuclear imaging and preclinical research involving radioisotopes will be significantly accelerated in the near future.

show abstract

“…Recently, there has been growing interest in the use of photons from Cherenkov radiation for optical imaging [4][5][6][7][8][9][10][11][12] and for excitation of quantum dots and fluorophores in vivo [6,8]. Charged particles such as β + and β − which are generated from radioactive isotope decay can result in visible light with a broad energy range (ca.…”

Section: Introductionmentioning

confidence: 99%

In Vivo Photoactivation Without “Light”: Use of Cherenkov Radiation to Overcome the Penetration Limit of Light

et al. 2011

View full text Add to dashboard Cite

Purpose: The poor tissue penetration of visible light has been a major barrier for optical imaging, photoactivatable conversions, and photodynamic therapy for in vivo targets with depths beyond 10 mm. In this report, as a proof-of-concept, we demonstrated that a positron emission tomography (PET) radiotracer, 2-deoxy-2-[ 18 F]fluoro-D-glucose ( 18 FDG), could be used as an alternative light source for photoactivation. Procedures: We utilized 18 FDG, which is a metabolic activity-based PET probe, as a source of light to photoactivate caged luciferin in a breast cancer animal model expressing luciferase. Results: Bioluminescence produced from luciferin allowed for the real-time monitoring of Cherenkov radiation-promoted uncaging of the substrate. Conclusion: The proposed method may provide a very important option for in vivo photoactivation, in particular for activation of photosensitizers for photodynamic therapy and eventually for combining radioisotope therapy and photodynamic therapy.

show abstract

Experimental Cerenkov luminescence tomography of the mouse model with SPECT imaging validation

Cited by 118 publications

References 25 publications

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Harnessing the Power of Radionuclides for Optical Imaging: Cerenkov Luminescence Imaging

In Vivo Photoactivation Without “Light”: Use of Cherenkov Radiation to Overcome the Penetration Limit of Light

Contact Info

Product

Resources

About